News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,334 Results
Type
Article (46291)
Company Profile (318)
Press Release (683725)
Section
Business (214215)
Career Advice (2303)
Deals (37472)
Drug Delivery (115)
Drug Development (84901)
Employer Resources (178)
FDA (16849)
Job Trends (15735)
News (363302)
Policy (34815)
Tag
Academia (2718)
Alliances (52549)
Alzheimer's disease (1360)
Approvals (16818)
Artificial intelligence (234)
Bankruptcy (376)
Best Places to Work (11953)
Biotechnology (200)
Breast cancer (237)
Cancer (1848)
Cardiovascular disease (148)
Career advice (1914)
CAR-T (140)
Cell therapy (389)
Clinical research (68391)
Collaboration (726)
Compensation (392)
COVID-19 (2715)
C-suite (177)
Data (1710)
Diabetes (237)
Diagnostics (6481)
Earnings (88213)
Employer resources (154)
Events (116347)
Executive appointments (608)
FDA (17820)
Funding (643)
Gene therapy (277)
GLP-1 (743)
Government (4612)
Healthcare (19419)
Infectious disease (2843)
Inflammatory bowel disease (135)
Interviews (370)
IPO (16988)
Job creations (4227)
Job search strategy (1640)
Layoffs (485)
Legal (8617)
Lung cancer (270)
Manufacturing (262)
Medical device (13564)
Medtech (13569)
Mergers & acquisitions (20879)
Metabolic disorders (635)
Neuroscience (1812)
NextGen: Class of 2025 (6848)
Non-profit (4674)
Northern California (2201)
Obesity (353)
Opinion (244)
Patents (183)
People (60124)
Phase I (21252)
Phase II (30046)
Phase III (22526)
Pipeline (805)
Postmarket research (2739)
Preclinical (8951)
Radiopharmaceuticals (252)
Rare diseases (358)
Real estate (6444)
Regulatory (23466)
Research institute (2452)
Resumes & cover letters (382)
Southern California (1890)
Startups (3852)
United States (19608)
Vaccines (669)
Weight loss (262)
Date
Today (137)
Last 7 days (818)
Last 30 days (2823)
Last 365 days (35477)
2025 (5576)
2024 (36346)
2023 (41179)
2022 (52380)
2021 (56996)
2020 (55560)
2019 (48480)
2018 (36666)
2017 (34025)
2016 (33726)
2015 (39549)
2014 (33435)
2013 (28592)
2012 (30712)
2011 (31378)
2010 (29344)
Location
Africa (842)
Arizona (220)
Asia (42194)
Australia (6816)
California (5034)
Canada (1765)
China (431)
Colorado (232)
Connecticut (238)
Europe (91536)
Florida (745)
Georgia (179)
Illinois (489)
Indiana (289)
Maryland (786)
Massachusetts (3865)
Michigan (205)
Minnesota (352)
New Jersey (1437)
New York (1437)
North Carolina (917)
Northern California (2201)
Ohio (177)
Pennsylvania (1142)
South America (1217)
Southern California (1890)
Texas (740)
Utah (157)
Washington State (487)
730,334 Results for "catalyst pharma group inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
January 21, 2025
·
4 min read
LSL Pharma Group Completes the Acquisition of Virage Santé
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, is pleased to announce the completion of the acquisition of Virage Santé, a company specializing in the manufacturing and marketing of natural health products, based in Lévis, Quebec.
June 18, 2024
·
3 min read
Press Releases
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
February 27, 2025
·
17 min read
Business
LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, is pleased to announce the results of its annual and special meeting of shareholders held in Montréal, Québec.
June 28, 2024
·
3 min read
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate at the upcoming Jefferies Global Healthcare Conference 2024 on Wednesday, June 5, 2024, in New York.
May 28, 2024
·
3 min read
Business
LSL Pharma Group Reports Record Revenues and Margins for the First Quarter 2024
LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the first quarter of fiscal year 2024 ended on March 31, 2024.
May 30, 2024
·
7 min read
Business
LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights
LSL PHARMA GROUP INC. reported its financial results for the year-ended December 31, 2023.
April 30, 2024
·
10 min read
Press Releases
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
February 13, 2025
·
2 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
May 29, 2024
·
3 min read
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
Catalyst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE.
May 30, 2024
·
4 min read
1 of 73,034
Next
